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Redirecting CD8 T cell immunity with self/tumor-specific affinity-matured T cell recep-
tors (TCRs) is a promising approach for clinical adoptive T cell therapy, with the aim to 
improve treatment efficacy. Despite numerous functional-based studies, little is known 
about the characteristics of TCR signaling (i.e., intensity, duration, and amplification) 
and the regulatory mechanisms underlying optimal therapeutic T cell responses. Using 
a panel of human SUP-T1 and primary CD8 T cells engineered with incremental affinity 
TCRs against the cancer-testis antigen NY-ESO-1, we found that upon activation, T cells 
with optimal-affinity TCRs generated intense and sustained proximal (CD3ζ, LCK) signals 
associated with distal (ERK1/2) amplification-gain and increased function. In contrast, in 
T cells with very high affinity TCRs, signal initiation was rapid and strong yet only transient, 
resulting in poor MAPK activation and low proliferation potential even at high antigen 
stimulation dose. Under resting conditions, the levels of surface TCR/CD3ε, CD8β, and 
CD28 expression and of CD3ζ phosphorylation were significantly reduced in those hypo-
responsive cells, suggesting the presence of TCR affinity-related activation thresholds. 
We also show that SHP phosphatases were involved along the TCR affinity gradient, but 
displayed spatially distinct regulatory roles. While PTPN6/SHP-1 phosphatase activity 
controlled TCR signaling initiation and subsequent amplification by counteracting CD3ζ 
and ERK1/2 phosphorylation, PTPN11/SHP-2 augmented MAPK activation without 
affecting proximal TCR signaling. Together, our findings indicate that optimal TCR signal-
ing can be finely tuned by TCR affinity-dependent SHP-1 and SHP-2 activity, and this may 
readily be determined at the TCR/CD3 complex level. We propose that these TCR affinity- 
associated regulations represent potential protective mechanisms preventing high affinity 
TCR-mediated autoimmune diseases.
Keywords: cancer immunotherapy, nY-esO-1 antigen, T cell receptor engineering, T cell receptor-peptide-major 
histocompatibility complex affinity, hyporesponsiveness, cD3ζ, erK1/2, shP-1 and shP-2 phosphatases
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inTrODUcTiOn
Adoptive transfer of tumor-reactive T cells has demonstrated that 
cytotoxic CD8 T cells are capable of mounting durable and pro-
tective immune responses against cancer. Owing to mechanisms 
of central tolerance, most of the self/tumor-specific T cells rec-
ognize their target with relatively low affinity/avidity compared 
to T cells recognizing non-self-antigens (1). Genetic engineering 
of cytotoxic CD8 T lymphocytes with affinity-optimized tumor-
specific T cell receptors (TCRs) represents an interesting option 
for optimizing adoptive T cell transfer therapy. However, while 
therapeutic T cells should have maximal anti-tumor cytotoxic-
ity and low side effects, such affinity-improved T cells may also 
induce on-target autoimmune reactivity against normal tissues 
expressing the same self-antigens (2). It is therefore important 
to improve our knowledge about the TCR affinity-mediated 
fine-tuning of T cell responses.
CD8 T cell responses are modulated by both the affinity of the 
TCR for its agonist pMHC complex and by the dose (density) 
of antigen present during T  cell priming and activation. Many 
experimental evidences, including clinical trials, have high-
lighted that at physiologically low antigen dose, maximal T cell 
function occurs within a window of optimal TCR-pMHC affinity/
half-lives, with short or long interactions adversely impacting on 
T cell function (3–10). Specifically, using a panel of engineered 
primary CD8 T  cells expressing TCRs of incremental affinities 
for the NY-ESO-1 antigen, we found that T cells with supraphysi-
ologically very high affinity TCRs lying above the optimal affinity 
window (KD between 5 and 1 µM) were functionally impaired (3, 
11, 12). This impairment could be gradually restored by augment-
ing the dose of antigen stimulation (3). Recent investigations 
have shown that pMHC dose and affinity for the TCR determine 
T  cell responses by triggering common (e.g., for proliferation) 
but also distinct (e.g., IL-2 expression) gene expression programs 
downstream of the TCR signaling pathway (13). Modeling-based 
analyses on therapeutic TCR-transduced NY-ESO-1-specific 
T cells further enabled to unravel a minimal signaling architecture 
combining antigen affinity as well as dose effects (5). Altogether, 
these reports highlight that complex TCR affinity and antigen 
dose-associated regulatory mechanisms (positive and negative 
feedback loops) become integrated within the TCR signaling 
pathway following T cell activation.
Upon TCR triggering, TCR-mediated cell signaling occurs in a 
coordinated cascade of biochemical events. The Src-family kinase 
LCK is first recruited to the TCR complex to phosphorylate the 
immune-receptor tyrosine-based activating motifs (ITAMs) 
that are present on the various CD3 chains of the TCR complex, 
initiating signal transduction (14). Once fully phosphorylated, 
CD3/ITAMs recruit the Syk-family ZAP-70 kinase, which also 
becomes activated by LCK. Active ZAP-70 next phosphorylates 
the trans-membrane protein LAT and SLP-76, forming a signalo-
some scaffold enabling diversification of the signal into several 
branches, including the more distal MAPK signaling module 
(15). Controlled expression and activity of TCR/CD3 molecules, 
kinases and phosphatases represent a central strategy exploited 
by T cells to calibrate their activation threshold during develop-
ment (16) and to produce a scaled T cell response, preventing 
immune overreactions and autoimmunity during inflammatory 
responses (17).
PTPN6/SHP-1 and PTPN11/SHP-2 are two important phos-
phatases that can be recruited by cell surface inhibitory receptors 
such as PD-1 or CTLA-4 (18). Mice with loss-of-function muta-
tion in SHP-1 develop the motheaten phenotype associated with 
a severe inflammatory disorder (19), whereas specific deletion 
of SHP-1 in T  cells enhances their proliferation potential (20). 
SHP-1 has been shown to globally counteract lymphocyte acti-
vation, notably by targeting proximal TCR signaling molecules 
such as LCK, ITAM/CD3ζ, LAT, and ZAP-70 (18). Unlike SHP-1, 
SHP-2 has been generally described as a positive regulator of 
T  cell signaling (21), by sustaining the proliferative responses 
through indirect MAPK/Ras activation (22). However, an inhibi-
tory effect for SHP-2 in controlling proximal TCR signaling has 
also been demonstrated (23). Notably, it recently became clear 
that SHP-2 preferentially dephosphorylate the CD28 T  cell 
costimulatory receptor instead of the TCR to suppress T  cell 
function, in response to PD-1 activation by PDL1 (24). As such, 
SHP-1 and SHP-2 are key players involved in signaling regulatory 
loops, adjusting the activation threshold during development 
(positive and negative selection) and calibrating peripheral T cell 
responses according to the nature and the affinity of the antigen 
(18). We previously reported that pharmacological inhibition of 
SHP-1 activity improved T cell function in all TCR-engineered 
T cells, and this correlated with the levels of SHP-1 phosphoryla-
tion along the TCR affinity gradient (25). Despite major efforts to 
understand how TCR-pMHC affinity modulates T cell specificity, 
function and on- or off-target toxicity (26), little is known about 
the TCR signaling characteristics of affinity-optimized T cells and 
the regulatory mechanisms (e.g., SHP-1 and SHP-2) involved in 
controlling T cell responsiveness according to affinity.
Here, we aimed at spatially and temporally dissect the impact 
of TCR-pMHC affinity on the signal intensity, amplification-gain 
and duration of the proximal (i.e., CD3ζ and LCK) and distal (i.e., 
ERK1/2) TCR signaling nodes. We further investigated the role 
of SHP-1 and SHP-2 phosphatases on those early TCR signaling 
events to evaluate their potential regulatory function. Collectively, 
optimal TCR affinity-mediated signaling depends on the fine-
tuned intensity and duration of ITAM/CD3ζ and LCK phospho-
rylation levels after TCR triggering, associated with greatest pCD3ζ 
to pERK amplification-gain. We also found that TCR-ligand 
affinity modulates the levels of the TCR/CD3ε complex, CD8β and 
CD28 expression as well as of phosphorylated ITAM/CD3ζ readily 
under steady-state conditions. Moreover, optimal TCR signaling, 
leading to maximal function is calibrated in part by both SHP-1 
and SHP-2 activity, which play distinct roles in the TCR signaling 
transduction cascade. These observations should help to define the 
best TCR signaling-mediated characteristics and promote the use 
of therapeutic affinity-engineered CD8 T cells.
Abbreviations: TCR, T  cell receptor; pMHC, peptide-major histocompatibility 
complex; A2, HLA-A*0201; LCK, lymphocyte-specific protein tyrosine kinase; 
ZAP-70, zeta chain of T cell receptor-associated protein kinase 70; LAT, linker for 
activation of T cells; SLP-76, SH2 domain-containing leukocyte protein of 76 kDa; 
MAPK, mitogen-activated protein kinases; PTPN6/SHP-1 and PTPN11/SHP-2, 
protein tyrosine phosphatase, non-receptor type 6 and type 11.
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MaTerials anD MeThODs
ethics approval
Human peripheral blood cells were obtained from healthy donors 
of the Blood Transfusion Center of the University of Lausanne. 
All donors had previously completed the Swiss National Medical 
questionnaire to verify that they fulfilled the criteria for blood 
donation and provided written informed consent for the use of 
blood samples in medical research after anonymization.
cell lines and Primary cD8 T 
lymphocytes
T cell receptor α knock-out HLA-A68pos (a member of the HLA-
A2 supertype) (27) SUP-T1 cells (ATCC CRL-1942) and HLA-
A2pos/TAP-deficient T2 cells (ATCC CRL-1992) were cultured at 
37°C and 5% CO2 in RPMI 1640 supplemented with 10% FCS, 
10 mM HEPES, penicillin (100 U/ml), and streptomycin (100 µg/
ml). Human primary HLA-A2pos or HLA-A2neg CD8 T lympho-
cytes were obtained from peripheral blood mononuclear cells 
(PBMCs) from healthy donors following positive enrichment 
using anti-CD8-coated magnetic microbeads (Miltenyi Biotec), 
and cultured at 37°C and 5% CO2 in RPMI supplemented with 
8% human serum and 150  U/ml recombinant human IL-2 
(rhIL-2, gift from GlaxoSmithKline). CD8 T lymphocytes were 
expanded by periodic (every 14–21  days) restimulation with 
1 µM PHA (Oxoid) and 30 Gy irradiated allogeneic PBMC as 
feeder cells.
lentiviral Production and cell 
Transduction
Cloning strategies and lentiviral production were performed as 
described previously (3, 11). The full-length codon-optimized 
TCR AV23.1 and TCR BV13.1 chain sequences of a dominant 
NY-ESO-1157–165-specific T  cell clone of patient LAU155 were 
cloned in the pRRL, third generation lentiviral vectors, as hPGK-
AV23.1-IRES-BV13.1 or hPGK-AV23.1-T2A-BV13.1 constructs. 
The T2A construct was further modified by introducing a (T48C) 
and a (S57C) point mutation in the alpha and beta TCR con-
stant region, respectively, to enhance preferential pairing (28). 
Structure-based amino acid substitutions were introduced into the 
wild-type (WT) TCR sequence using the QuickChange mutagen-
esis kit (Stratagene) and all mutations were confirmed by DNA 
sequencing. Concentrated supernatant of lentiviral transfected 
293T/17 cells were used to infect SUP-T1 (15  min at 37°C) or 
primary CD8 T lymphocytes (overnight at 37°C). PE-labeled A2/
NY-ESO-1157–165-specific multimers were used to sort transduced 
primary CD8 T cells in order to enrich for multimer-positive cells 
by flow cytometry (FACS Vantage SE machine; BD Biosciences). 
Integrated lentiviral copy number was relatively equivalent for 
each TCR variant and for each transduced cell type; i.e., 8–10 
lentivirus copies/genome of SUP-T1 cells and 1–2 copies/genome 
of CD8 T cells (3).
Flow cytometry analysis
For analysis of surface protein expression, 2.5  ×  105 TCR-
transduced SUP-T1 or primary CD8 T  cells were washed and 
stained with the following antibodies: panTCRαβ-PE, BV13.1-PE, 
TCR/CD3ε-FITC, and CD8β-FITC (Beckman Coulter). All 
experiments were performed under unstimulated, resting culture 
conditions. For total TCR/CD3ε protein expression analysis, 
unstimulated cells were fixed and permeabilized according to 
the phospho-flow assay protocol (see thereafter). Samples were 
acquired with a Gallios (Beckman Coulter) flow cytometer. 
FlowJo software (Tree star) and Prism software (GraphPad, USA) 
were used for data analyses.
Phospho-Flow assay
For phospho-flow staining experiments, 2.5  ×  105 TCR-
transduced primary CD8 T cells or SUP-T1 cells were either left 
unstimulated or stimulated for the indicated period of time at 
37°C with unlabeled A2/NY-ESO-1157–165 multimers (TC Metrix 
Sàrl, Switzerland) at final concentrations ranging from 0.001 to 
100  µg/ml. For control experiments, TCR-transduced primary 
CD8 T  cells or SUP-T1 cells were stimulated with 1  µg/ml 
PMA/250 ng/ml Ionomycin or with OKT3 anti-CD3ε antibody 
(10 µg/ml) for 5 min. The reaction was stopped immediately by fix-
ing the cells with 4% paraformaldehyde (Polysciences) for 10 min 
at 37°C. Cells were permeabilized with 100% ice-cold methanol 
(Sigma Aldrich) for 20 min on ice and stained with the following 
antibodies: anti-phospho-ERK1/2 Alexa Fluor® 647 (T202/Y204 
of ERK1 and T185/Y187 of ERK2, Clone: E10, Cell Signaling 
Technology), antiphospho-CD3ζ (CD247) Alexa Fluor647 (Y142, 
Clone: K25-407.6, BD Phosflow), and unconjugated antitotal 
SHP-1 (ID:Y476, GeneTex) for 30 min at room temperature. For 
total SHP-1 staining, samples were further stained with FITC-
conjugated goat antirabbit IgG (BD Pharmingen) for 20 min at 
4°C. Samples were acquired with a Gallios (Beckman Coulter) or 
an ImageStream Mark II (Merck) flow cytometer. Representative 
cell images [geometric mean fluorescence intensity (gMFI) values 
corresponding to the population average] from the ImageStream 
analysis were blindly chosen by an independent collaborator. For 
the data analyses, FlowJo software (Tree star) and Prism software 
(GraphPad, USA) were used.
Western Blot analysis
For Western blot analyses, 1 × 106 TCR-transduced SUP-T1 cells 
were either left unstimulated or stimulated for the indicated 
time points with unlabeled A2/NY-ESO-1157–165 multimers (TC 
Metrix Sàrl, Switzerland) at a final concentration of 1 µg/ml at 
37°C. The reaction was stopped via ice-cold phosphate-buffered 
saline (PBS) and cells were lysed with RIPA buffer containing 
protease and phosphatase inhibitors (cOmplete and PhosSTOP, 
Roche). Protein quantification of the lysates was done using 
the Pierce BCA Protein Assay (Thermo Fisher Scientific, USA). 
5–20 µg of denatured and reduced protein lysates were separated 
by SDS-PAGE followed by wet electrotransfer to nitrocellulose 
membranes. Membranes were blocked with 5% BSA or dry milk 
(in TBS-0.1% Tween 20) for 1 h at room temperature and subse-
quently immunoblotted overnight at 4°C. The following primary 
antibodies were used: antiphospho-CD3ζ (CD247) (pY142, clone 
K25-407.6; BD Pharmingen) and antiphospho-SHP-2 (Tyr580, 
clone D66F10, Cell Signaling Technology). Membranes were 
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stained with HRP-conjugated species-specific secondary Abs for 
1 h at room temperature. Anti-α-tubulin (B-5-1-2, Sigma Aldrich) 
was used as a loading control. The chemiluminescent signal was 
revealed by Western Bright ECL HRP substrate (Advansta) and 
images were acquired either with the Fusion FX (Vilber Lourmat) 
imaging system or by exposing the membrane to an X-ray film 
(Amersham Hyperfilm ECL, General Electric).
reverse-Phase Protein assays (rPPa)
For all experiments, 1 × 106 TCR-transduced SUP-T1 cells were 
resuspended in 100  µl complete prewarmed RPMI medium, 
and either left unstimulated (baseline) or stimulated with 100 µl 
prewarmed RPMI complete medium containing unlabeled A2/
NY-ESO-1157–165 multimers at a final concentration of 1  µg/ml 
for 30  s or 1, 2, or 5  min. To stop the reaction, the cells were 
immediately put on ice, washed with 5  ml ice-cold PBS with 
freshly prepared protease and phosphatase inhibitors (cOmplete 
and PhosSTOP, Roche), and centrifuged in a cold bench top 
centrifuge for 5  min at 450  g. Supernatant was discarded and 
protein extracts were obtained by gently resuspending the cell 
pellets on ice for 40 min with 40 µl ZeptoMARK CLB-96 lysis 
buffer (3.5 M urea, 1 M thiourea, 0.4% CHAPS, 0.1% DTT, 5% 
DMSO, 10% glycerol, 0.4 mM spermidin, 0.2% pharmalyte, 1% 
octil-β-glucoside, and 1 mM sodium orthovanadate) containing 
freshly added protease and phosphatase inhibitors (cOmplete 
and PhosSTOP, Roche). Upon lysis, cell lysates were quickly 
frozen on dry ice and put at −80°C.
Reverse-phase protein assays were performed essentially as 
described (29). Cell lysates were quantified and serially diluted 
with CLB-96 lysis buffer before being spotted on ZeptoMARK 
chips, washed with assay buffer CAB1 (50  mM imidazole, 
100 mM NaCl, 0.1% Tween 20, 5% BSA), and stained overnight at 
room temperature with a primary antibody against the protein of 
interest: total anti-LCK/Src (clone D88), anti-pLCK/pSrc (Y394/
Y416), and anti-pSHP-2 (Y580 or Y542) from Cell Signaling, 
total anti-SHP-1 (C-19) and total anti-SHP-2 (C-18) from Santa 
Cruz, and anti-pSHP-1 (Y536, SP1571) from ECM Biosciences. 
Chips were washed with assay buffer CAB1 and incubated for 
1 h at room temperature in the dark with a corresponding (anti-
mouse or antirabbit) fluorescently labeled secondary antibody 
for signal generation. The fluorescent (Alexafluor 647-labeled) 
antibody was washed out with assay buffer CAB1, and chips were 
subsequently scanned with a ZeptoREADER microarray reader 
(Zeptosens, Witterswil, Switzerland).
cell Proliferation assay
Native NY-ESO-1157–165 peptides were preincubated for 1  h at 
room temperature with the disulfide-reducing agent TCEP 
(2 mM, Pierce Biotechnology). 30-Gy irradiated HLA-A*0201-
positive PBMCs were pulsed 1  h at 37°C with the indicated 
concentration of NY-ESO-1157–165 peptide, washed and incubated 
with CellTraceViolet-stained (Thermo Fisher), TCR-transduced 
primary CD8 T cells at an E:T ratio of 1:2 in RPMI 1640 medium 
supplemented with 8% human serum and 50 U/ml human rIL-2 
(gift of GlaxoSmithKline). After 7 days, cells were acquired on a 
Gallios (Beckman Coulter, CA, USA) flow cytometer. Analysis of 
the data was done with the FlowJo software (Tree Star).
Pharmacological inhibition of shP-1 and 
shP-2 Phosphatase activities
For pharmacological SHP-1 and SHP-2 inhibition, 105 TCR-
transduced SUP-T1 or primary CD8 T  cells were treated with 
sodium stibogluconate (SSG) (100 µg/ml Sb content; Santa Cruz 
Biotechnology, Santa Cruz, CA) for 3  days, a concentration 
expected to inhibit both phosphatase activities (30). Cells were 
then stimulated, fixed, permeabilized, and stained with pERK1/2 
or pCD3ζ (Y142) antibodies using the phospho-flow assay and 
analyzed on a flow cytometer.
crisPr/cas9 constructs Targeting SHP-1 
and SHP-2 genes
The 20 nucleotide-single guide RNA (sgRNA) sequences against 
SHP-1 and SHP-2 were designed using http://CRISPR.mit.edu/ and 
selected for high-quality scores (above 90 and 70, respectively) to 
minimize off-target effects. The guide sequences for the targets were 
as follows: SHP-1 (sgRNA no 3–4 TGAGTTCTGGATCCGAATAT) 
and (sgRNA no 5–6 TCACCCTGGTTCTTGCGACT); SHP-2 
(sgRNA no 9–10 GTGCGCACTGGTGATGACAA). An extra 5′ 
G nucleotide was added to all guide sequences to improve U6 pro-
moter efficiency. sgRNAs were generated by annealing DNA oligos 
and subsequently ligated into a BsmBI-digested lentiCRISPR plas-
mid (Addgen #49535). LentiCRISPR-EGFP-6 (a gift from Feng 
Zhang—Addgene plasmid #51765) was used as a mock control. 
Plasmids expressing SHP-1-, SHP-2-, or control (EGFP)-specific 
CRISPR/Cas9 constructs were transfected in HEK 293T/17 cells 
(ATCC CRL-11268) using a standard calcium phosphate protocol 
for the production of lentiviral particles. Lentiviral-containing 
supernatant was harvested twice (24 and 48 h post-transfection), 
filtrated, and concentrated 300× by ultracentrifugation. 0.5 × 106 
SUP-T1 cells stably expressing the different NY-ESO-1-specific 
TCR variants were then transduced with concentrated lentiviral 
particles for 15 min at 37°C. Two days after transduction, newly 
transformed puromycin-resistant SUP-T1 cells were selected in 
puromycin-containing RPMI 10% FCS medium (1  µg/ml) for 
7 days. The penetrance of the knock-out phenotype was verified 
by Western blot or flow cytometry before further usage.
statistical analysis
Data were analyzed using the Prism software (v.6, GraphPad) 
by matched one-way ANOVA followed by Dunnett’s multiple 
comparisons, by matched, two-way ANOVA followed by Tukey’s 
multiple comparisons or by two-tailed, paired t tests. The associ-
ated p values at α = 0.05 as well as numbers of experiments and 
sample sizes are indicated throughout the manuscript.
resUlTs
intensity of erK1/2 activation following 
antigen-Dependent or -independent Tcr/
cD3 Triggering Depends on Tcr-ligand 
affinity
Using a panel of TCR-engineered A2/NY-ESO-1-specific 
SUP-T1 and primary CD8 T  cells (3, 12), we first assessed the 
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impact of TCR-pMHC affinity on the distal pERK1/2 signaling 
node in terms of signal intensity and duration by quantitative 
flow cytometry-based intracellular staining (i.e., phospho-flow) 
and RPPA. Baseline levels of pERK1/2 were low and similar 
for all TCR affinity variants (Figures 1A,B,D–F; Figure S1A in 
Supplementary Material). Upon antigen-specific TCR triggering 
with pMHC multimers, ERK1/2 phosphorylation displayed an 
on-off activation pattern at the population level, from pERK1/2low 
to pERK1/2high (Figures 1A,D,E), consistent with the previously 
reported switch-like digital response of ERK1/2 activation (31). 
We found strongest pERK1/2 levels and superior signal persistence 
in SUP-T1 and CD8 T cells expressing TCRs within the optimal 
affinity window (DMβ and TMβ), with a time-to-peak between 2 
and 5 min (Figures 1B,D; Figure S1A in Supplementary Material). 
In contrast, T  cells expressing very high affinity TCRs (QMα 
and wtc51m) exhibited both reduced ERK1/2 phosphorylation 
intensity and duration, resembling the ERK1/2 signaling pattern 
observed in T cells with lower affinity TCRs (V49I and wild-type). 
Yet, comparable levels of total ERK1/2 expression were observed 
for all TCR variants (Figure S1B in Supplementary Material).
We next asked whether this decline in ERK1/2 signaling is an 
intrinsic feature of T cells with very high affinity TCRs (hereafter 
called “very high affinity T cells”) or whether it highlights the pres-
ence of TCR affinity-dependent signal inhibitory mechanisms. 
To do so, SUP-T1 and primary CD8 T  cells were stimulated in 
parallel experiments with either NY-ESO-1 multimers (antigen-
specific/TCR-dependent) or OKT3 antibody (antigen-unspecific/
TCR-dependent) or PMA/Ionomycin (antigen-unspecific/TCR-
independent) (Figures 1C,E,F). Whereas antigen-specific TCR trig-
gering with multimers recapitulated the typical bell-shape pattern, 
PMA/Ionomycin generated comparable ERK1/2 phosphorylation 
levels (i.e., fold change and fraction of pERK-responding cells) 
for each TCR variant, irrespective of TCR affinity. Interestingly, 
TCR crosslinking with the strong anti-CD3ε/OKT3 antibody 
produced an ERK1/2 phosphorylation pattern, which inversely 
correlated with TCR affinity. Very high affinity T cells showed again 
reduced ERK1/2 phosphorylation levels, while lower affinity T cells 
responded more vigorously to OKT3 (Figures 1C,E,F).
Extending on our previous report (25), these results show that 
the MAPK signaling node remains functional in all engineered 
SUP-T1 and primary CD8 T cell variants, with maximal ERK1/2 
activation intensity and duration observed in T  cells of optimal 
TCR affinities. However, ERK1/2 phosphorylation was reduced in 
the very high affinity T cells when induced by antigen-dependent 
or non-dependent TCR/CD3 triggering, suggesting the presence 
in those cells of negative regulators of the TCR signaling pathway. 
Conversely, the diminished ERK1/2 activation pattern observed in 
the low affinity V49I expressing T cells following antigen-specific 
but not antigen-independent TCR triggering is likely related to the 
poor intrinsic binding affinity of this particular TCR variant (3, 11).
Optimal Tcr affinity-Mediated signaling 
Depends on the Fine-Tuned intensity and 
Duration of Phosphorylated iTaM/cD3ζ 
levels
To investigate whether the high TCR affinity-associated impair-
ment of distal ERK1/2 phosphorylation is readily detectable at 
the proximal level of the TCR signaling cascade, we quantitatively 
assessed the intensity and duration of CD3ζ phosphorylation 
in SUP-T1 cell variants following antigen-specific stimulation 
(Figure  2). Upon TCR triggering, the relative amplitude (i.e., 
fold change between baseline and activated state) of pCD3ζ 
(Y142) phosphorylation gradually increased along the TCR 
affinity gradient, and was predominant in the supraphysiologi-
cal T cells (QMα, wtc51m) at early time-points (Figures 2A,B). 
Accordingly, the very high affinity T  cells were the first to 
generate fully active pCD3ζ 23 kDa complexes (Figures 2C,D), 
as depicted by the gel shift from 21 to 23 kDa (14). This trend 
progressively reversed over time in favor of the optimal affinity 
TCR variants (DMβ and TMβ), which displayed the highest 
intensity and longest duration of fully phosphorylated ITAM/
CD3ζ 23 kDa (Figures 2C,D).
Using RPPA, we next quantified the phosphorylation levels 
of the activatory pLCK(Y394) form and found no changes for 
the baseline levels of pLCK or total LCK (Figures S2A,C in 
Supplementary Material) between the different TCR variants. 
Upon activation however, the levels of pLCK(Y394) rose rapidly 
(<30 s) in a TCR affinity-dependent manner from low to very 
high affinity TCR variants, thus preceding ITAM/CD3ζ phospho-
rylation with similar activation and kinetic patterns. No major 
changes were observed for the inhibitory pLCK(Y505) form 
at baseline or upon stimulation (Figure S2B in Supplementary 
Material). These observations indicate that despite its relatively 
high initial intensity, the proximal TCR signaling potential of 
very high affinity T cells remains transient. Thus, optimal TCR 
affinity-mediated signaling depends on the fine-tuned intensity 
and duration of ITAM/CD3ζ and LCK phosphorylation after 
TCR triggering.
Tcr-ligand affinity Modulates expression 
and Phosphorylation levels of the Tcr/
cD3 complex readily Under steady-state 
conditions
We previously observed that baseline surface expression of 
several activatory/costimulatory receptors (e.g., CD28, HVEM, 
and CD70) was significantly reduced in CD8 T cells of high TCR 
affinity (25). Here, we investigated whether the surface expres-
sion pattern of TCR/CD3 complex as well as the phosphorylation 
levels of CD3ζ and ERK1/2 could similarly be decreased in TCR-
transduced SUP-T1 and newly engineered primary CD8 T cells 
under steady-state conditions, in the absence of antigenic stimu-
lation. We observed that high affinity SUP-T1 cells (QMα and 
wtc51m) displayed substantially lower levels of surface TCRαβ 
and CD3ε as well as of phosphorylated ITAM/CD3ζ (Y142), 
while maintaining comparable expression levels of total (i.e., 
intracellular and extracellular) CD3ε complexes and pERK1/2 
(Figures  3A–C). These data were confirmed by Western blot 
analyses (Figures 2C,D), showing in those cells reduced levels of 
pCD3ζ 21 kDa, a partially phosphorylated form of CD3ζ mostly 
found under resting culture conditions (32). Similar differences 
were found in the primary CD8 T  cells with reduced levels of 
overall TCRαβ, TCR β-chain (BV13.1) and CD8β in very high 
affinity T cells (Figures 3D,E). A slight decline in surface levels 
of CD3ε could also be observed in these cells (Figure 3E), albeit 
A B C
D E F
FigUre 1 | Continued
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FigUre 1 | Continued  
Temporal quantification of distal ERK1/2 phosphorylation levels in T cells engineered with T cell receptor (TCR) of incremental affinities. (a) Representative histograms 
of the phosphorylation levels of ERK1/2 by phospho-flow at baseline (gray) and the indicated time-points (color) of TCR-transduced SUP-T1 stimulated with 
NY-ESO-1-specific unlabeled multimers. KD affinity values (μM) (3) for each TCR variant are indicated. (B) Quantification of pERK1/2 levels [geometric mean 
fluorescence intensity (gMFI)] for the TCR-transduced SUP-T1 variants (n > 6 independent experiments) at baseline, 5, 10, and 30 min poststimulation with NY-ESO-1-
specific unlabeled multimers. (c) Relative intensity of ERK1/2 phosphorylation levels for the indicated TCR affinity variants (n = 6 independent experiments) after 5 min 
stimulation with NY-ESO-1-specific unlabeled multimers (top panel), PMA/ionomycin (middle), or OKT3 (anti-CD3ε) antibody (bottom). Data are depicted as box (25th 
and 75th percentile) and whisker (min to max) with the middle line representing the median. (D) Representative histograms of the phosphorylation levels of ERK1/2 by 
phospho-flow at baseline (gray) and at the indicated time-points (color) of TCR-transduced primary CD8 T cells stimulated with NY-ESO-1-specific unlabeled 
multimers. (e) Representative histograms of the phosphorylation levels of ERK1/2 by phospho-flow at baseline (gray) and at 5 min (color) of TCR-transduced primary 
CD8 T cells stimulated with OKT3 (anti-CD3ε) antibody or PMA/Ionomycin. (F) Positive fraction of ERK1/2 phosphorylation in primary CD8 T cells expressing the 
indicated TCR affinity variants (n ≥ 6 independent experiments) at baseline (gray) and after 5 min stimulation with NY-ESO-1-specific unlabeled multimers (top panel), 
PMA/ionomycin (middle) or OKT3 (anti-CD3ε) antibody (bottom). Statistical analyses were performed with matched, one-way ANOVA tests followed by Dunnett’s 
multiple comparisons. Significance of the adjusted p value at α = 0.05 is given by the following symbols: ns (p > 0.05) and *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, 
****p ≤ 0.0001. (a–F) ERK1/2 phosphorylation levels obtained by phospho-flow for each TCR variant are depicted by distinct symbols and color codes.
FigUre 2 | Continued
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FigUre 3 | Baseline expression levels of the T cell receptor (TCR)/CD3 complex in SUP-T1 and primary CD8 T cells engineered with TCR of incremental affinities. 
(a–c) Quantification of the expression (a–B) and phosphorylation (c) levels [geometric mean fluorescence intensity (gMFI)] of unstimulated, baseline (a) pan TCRαβ 
and TRBV13.1, (B) extracellular CD3ε and total intra- and extracellular CD3ε, and (c) CD3ζ (Y142) and ERK1/2(T202/Y204) for the indicated TCR-transduced 
SUP-T1 variants. Data are representative of 5–20 independent experiments. (D–e) Quantification of the expression levels (gMFI) of unstimulated, baseline (D) pan 
TCRαβ and TRBV13.1 and (e) extracellular CD3ε and CD8β for the indicated TCR-transduced primary CD8 T cell variants. Data are representative of 6–15 
independent experiments. (F) Quantification of the CD28 expression levels for the indicated TCR-transduced primary CD8 T cells isolated from an HLA-A2pos (left 
panel) or an HLA-A2neg (right panel) healthy donor under resting, unstimulated culture conditions. Data are representative of three to nine independent experiments 
(a–F) Statistical analyses were performed with matched, one-way ANOVA tests followed by Dunnett’s multiple comparisons. Significance of the adjusted p value at 
α = 0.05 is given by the following symbols: **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. Each TCR variant is depicted by a distinct symbol and color code.
FigUre 2 | Continued  
Temporal quantification of proximal CD3ζ phosphorylation levels in T cells engineered with T cell receptor (TCR) of incremental affinities. (a) Representative histograms 
of the phosphorylation levels of CD3ζ (Y142) at baseline (gray) and the indicated time-points (color) of TCR-transduced SUP-T1 variants stimulated with NY-ESO-1-
specific unlabeled multimers. (B) Quantification of the absolute intensity [left panels, geometric mean fluorescence intensity (gMFI)] and relative intensity (right panels, 
fold change) of pCD3ζ (Y142) by phospho-flow for the indicated TCR-transduced SUP-T1 variants at 1, 5, and 30 min poststimulation with NY-ESO-1-specific 
unlabeled multimers (n > 10 independent experiments). (c) Levels of steady-state 21 kDa and fully activated 23 kDa immune-receptor tyrosine-based activating motif 
(ITAM)/pCD3ζ complexes of TCR-transduced SUP-T1 variants at baseline and at the indicated time-points after stimulation with NY-ESO-1-specific unlabeled 
multimers. Alpha-tubulin expression levels were used as loading controls between samples. Data are representative of four independent Western blot experiments. 
(D) Quantification of the relative pixel intensities of the baseline 21 kDa and fully activated 23 kDa ITAM/pCD3ζ bands detected by Western blot and normalized to 
α-tubulin in the TCR-transduced SUP-T1 variants at the indicated time-points after stimulation with NY-ESO-1-specific unlabeled multimers (n = 4 separate 
experiments). (B,D) Data are depicted as box (25th and 75th percentile) and whisker (min to max) with the middle line representing the median. Statistical analyses 
were performed with matched, one-way ANOVA tests followed by Dunnett’s multiple comparisons. Significance of the adjusted p value at α = 0.05 is given by the 
following symbols: ns p > 0.05 and *p ≤ 0.05, **p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. (a,B,D) Each TCR variant is depicted by a distinct symbol and color code.
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baseline CD3ζ and ERK1/2 phosphorylation levels remained 
stable throughout the whole affinity panel (Figure S2D in 
Supplementary Material). The phenotypical variations observed 
between the SUP-T1 and the primary CD8 T cells might reflect 
the presence of the endogenous TCR/CD3 complexes expressed 
in the latter cells, but absent in the SUP-T1 cell line. Consistent 
with our previous report (25), lower expression of CD28 was 
found in supraphysiological CD8 T cells. In contrast, no marked 
decline in CD28 and TCR β-chain (BV13.1) expression was seen in 
TCR-engineered CD8 T cells lacking HLA-A2 expression (Figure 
3F, preliminary unpublished data). Altogether, these results show 
that TCR-ligand affinity readily impacts on the expression levels 
of surface TCR/CD3ε, CD8β, and CD28 as well as of activated 
ITAM/CD3ζ at baseline, under resting conditions.
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Both Tcr-ligand affinity and antigen 
Dose Modulate the strength and 
amplification of the Tcr-Mediated 
signaling Pathway
T  cell receptor stimulation with high doses of antigen can 
modulate T cell functional output in a TCR affinity-dependent 
manner (3, 5, 10, 33). In line with these previous reports, we 
found that enhanced density of NY-ESO-1 antigen increased 
the proportion of primary CD8 T  cells capable to degranulate 
CD107a and produce cytokines, with the low (V49I) and very 
high (wtc51m) affinity T cells still requiring higher antigen doses 
than the other variants to reach maximum levels (Figure S3 in 
Supplementary Material). In contrast to the relative recovery in 
CD107a degranulation and cytokine secretion observed in the 
very high affinity CD8 T cells, both proliferation and expansion 
capacity of those cells remained reduced even at high, saturating 
antigen doses (Figures  4A,B). Thus, increase in antigen dose 
was unable to fully restore the proliferative capacity of the very 
high affinity primary CD8 T cells when compared to the optimal 
variants (DMβ and TMβ).
To gain further insights into the mechanisms underlying the 
impaired proliferative capacity associated with low and very 
high TCR affinity variants, we explored the impact of increased 
antigen doses on proximal (ITAM/pCD3ζ) and distal (pERK1/2) 
signaling efficiency (Figures 4C–H). We found that the phospho-
rylation pattern of CD3ζ steadily increased in each engineered 
SUP-T1 variant along the antigen dose, with absolute pCD3ζ 
(Y142) levels being higher in optimal affinity TCR variants (DMβ 
and TMβ) at all multimer concentrations (Figure 4C). Yet, the 
maximal amplitude of pCD3ζ signal (i.e., fold change from base-
line to maximum activated levels) was comparable along the dif-
ferent TCR variants (Figure 4E). At the MAPK node, increasing 
the antigen dose also allowed discriminating different pERK1/2 
phosphorylation levels (Figure 4D), but this time optimal affin-
ity T cells presented significantly higher signal amplitude when 
compared to low (V49I, wild-type) and very high affinity (QMα, 
wtc51m) T cells (Figure 4F). As expected, the sensitivity of TCR 
triggering (i.e., EC50) similarly increased along TCR affinity 
for both signaling nodes, with ERK1/2 phosphorylation being 
on average 25-fold more sensitive than pCD3ζ (Figure  4G). 
Finally, signal transduction and amplification from proximal 
pCD3ζ to distal pERK1/2 was not only stronger, but also more 
sustained within the optimal TCR affinity window (DMβ, TMβ) 
(Figure 4H; Figure S2E in Supplementary Material). This result 
shows that optimal TCR-pMHC interactions are able to generate 
significant ERK1/2 phosphorylation despite relatively low levels 
of pCD3ζ activation (e.g., at antigen concentration 10−1  µM) 
(Figure 4H), in agreement with the model of positive forward 
loops acting through ERK1/2 responses (31).
In summary, these titration experiments indicate that TCR 
affinity and antigen dose-associated mechanisms differentially 
affected the amplitude and amplification-gain of the TCR signal-
ing pathway. Optimal TCR affinity-mediated signaling responses 
correlated with highest pCD3ζ and pERK1/2 activation levels as 
well as with greatest pCD3ζ to pERK1/2 amplification-gain for 
all tested antigen doses. Increased antigen doses did not allow the 
recovery of maximal pCD3ζ and pERK1/2 levels for low and very 
high TCR affinity T cells, leading to reduced signal amplitude and 
amplification-gain at the distal ERK1/2 signaling node. These data 
further support the hypothesis of an active regulatory mechanism 
present in the very high affinity CD8 T cells and impinging on 
the ERK1/2-signaling node, providing an explanation for the 
impaired proliferation capacity observed in these cell variants.
Pharmacological inhibition of shP-1/
shP-2 Phosphatase activity Differentially 
impacts Proximal and Distal Tcr 
signaling nodes, Depending on Tcr 
affinity
SHP-1 and SHP-2 phosphatases play critical roles in regulating 
peripheral CD8 T cell responses, notably by controlling TCR-
mediated cell signaling and function (23, 34, 35). We previously 
reported gradual enhanced levels of SHP-1 phosphorylation 
[pY536 (36)] with increasing TCR affinities in primary CD8 
T  cells (25). Here, using the RPPA quantitative approach, we 
confirmed that following antigen-specific stimulation, SHP-1 
phosphorylation was increased in the very high affinity SUP-T1 
cells compared to optimal and low affinity TCR variants (Figure 
S4 in Supplementary Material). Extending these observations, 
we now demonstrate a rapid (30 s) and TCR affinity-associated 
upregulation for the two major phospho-forms of SHP-2 
(pY580 and pY524) (37) (Figures 5A,B), contrasting with the 
stable levels observed for total SHP-2 (Figure 5C). Western blot 
analyses further revealed that highest levels of SHP-2 phospho-
rylation were readily found at baseline in high affinity T cells 
(Figure 5D), in line with the results found for SHP-1 activation 
levels (25).
To investigate whether SHP-1 and SHP-2 activity could 
proportionately impact TCR-mediated signaling, SUP-T1 and 
primary CD8 T  cells were pretreated with the SHP-1/SHP-2 
inhibitor SSG, at a concentration expected to inhibit both 
phosphatase activities (30). We assessed the activation levels 
of CD3ζ and ERK1/2 before and after antigen-specific TCR 
stimulation. Under steady-state conditions, both pCD3ζ and 
pERK1/2 baseline levels remained stable and mostly unaffected 
by the SSG-mediated phosphatase blockade. Upon antigen-
specific stimulation, pharmacological inhibition of SHP-1/
SHP-2 activity profoundly affected ERK1/2 phosphorylation 
and to a less extent pCD3ζ (Y142), in a TCR affinity-dependent 
manner (Figures 6A,B; Figure S5 in Supplementary Material). 
Specifically, the potential of ERK1/2 phosphorylation (i.e., the 
fraction of pERK-responding cells and its fold change in the 
presence versus absence of SSG) was reduced in low (V49I, 
wild-type) and optimal (DMβ, TMβ) affinity TCR variants 
(Figures  6B,C; Figures S5B,C in Supplementary Material). In 
contrast, the very high (QMβ, wtc51m) affinity variants showed 
a better resistance to the inhibitory effect of the drug, because 
treated SUP-T1 and CD8 T  cells were able to maintain stable 
pERK1/2 levels. Thus, despite an overall reduced ERK1/2 phos-
phorylation, relative changes in ERK1/2 activation following 
SSG treatment now increased with the TCR affinity gradient 
after antigenic stimulation, with greatest levels being found in 
A B
C E G
D F H
FigUre 4 | Effect of antigen dose on proliferation and T cell receptor (TCR)-mediated signal intensity and amplification of pCD3ζ and pERK1/2. (a) Proliferation 
analysis performed at day 7 for the indicated variant of CFSE-labeled, TCR-transduced primary CD8 T cells after stimulation with titrating doses of NY-ESO-1 
antigen-pulsed irradiated PBMCs. (B) Quantification of the percentage of divided cells (frequency of dividing cells) from the proliferation histograms shown in (a). 
Data obtained from the different antigen doses (0.01, 0.1, and 1 µM) are depicted as individual graphs. (c,D) Average phosphorylation levels of (c) CD3ζ (Y142) 
(n = 5 independent experiments) and (D) ERK1/2 (n = 5) by phospho-flow following stimulation at 5 min of the indicated TCR-transduced SUP-T1 variants with 
titrating doses of NY-ESO-1-specific unlabeled multimers. (e,F) Quantification of the signal amplitude (from minimal to maximal Emax level) of (e) pCD3ζ (Y142) and 
(F) pERK1/2 for the indicated TCR-transduced SUP-T1 variants. Statistical analyses were performed with matched, one-way ANOVA tests followed by Dunnett’s 
multiple comparisons. Significance of the adjusted p value at α = 0.05 is given by the following symbols: ns p > 0.05 and *p ≤ 0.05, **p ≤ 0.01. (g) Quantification of 
the EC50 antigen dose producing half of the maximal signal amplitude for pCD3ζ (Y142) (open symbols) and pERK1/2 (plain symbols) for the indicated TCR-
transduced SUP-T1 variants. (h) Quantification of the signal amplification gain (relative fold increase) from pCD3ζ (Y142) to pERK1/2 following 5 min stimulation of 
the indicated TCR-transduced SUP-T1 variants with titrating doses of NY-ESO-1-specific unlabeled multimers. (c–h) Each TCR variant is depicted by a distinct 
symbol and color code.
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the very high TCR variants. Interestingly, SSG treatment had an 
opposite effect on pCD3ζ (Y142) levels, with a modest increase 
in all variants (Figures  6B,C; Figure S5B,C in Supplementary 
Material). Yet, this trend was more pronounced in the very high 
affinity T  cells. Together, our data suggest that SHP-1 and/or 
SHP-2 activity may have a distinct impact on the proximal and 
distal TCR signaling nodes, and this was dependent on TCR-
pMHC affinity.
A B
C D
FigUre 5 | Temporal quantification of SHP-2 phosphorylation levels in T cells engineered with T cell receptor (TCR) of incremental affinities. (a–c) Relative intensity 
of (a) pSHP-2(Y580) (n = 4 independent experiments), (B) pSHP-2(Y542) (n = 5), and (c) total SHP-2 (n = 3) levels obtained by RPPA at baseline and at the 
indicated time-points after stimulation of the SUP-T1 cells with NY-ESO-1-specific unlabeled multimers. Data are depicted as box (25th and 75th percentile) and 
whisker (min to max) with the middle line representing the median. Each TCR variant is depicted by distinct color codes. Statistical analyses were performed with 
matched, one-way ANOVA tests followed by Dunnett’s multiple comparisons. Significance of the adjusted p value at α = 0.05 is given as following: *p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. (D) Levels of pSHP-2(Y580) of TCR-transduced SUP-T1 variants at baseline and at the indicated time-points after 
stimulation with NY-ESO-1-specific unlabeled multimers by Western blotting. Alpha-tubulin expression levels were used as loading controls between samples. Data 
are representative of three independent experiments.
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A B C
FigUre 6 | Effect of sodium stibogluconate (SSG) on proximal CD3ζ and distal ERK1/2 phosphorylation levels in T cell receptor (TCR)-engineered primary CD8 
T cells. (a) Representative histograms of the phosphorylation levels [geometric mean fluorescence intensity (gMFI)] of ERK1/2 (left) and CD3ζ (Y142) (right) by 
phospho-flow at baseline (gray) and 5 min poststimulation with NY-ESO-1-specific unlabeled multimers (color) of TCR-transduced primary CD8 T cell variants 
pretreated (SSG) or not (mock) with SSG. (B) Quantification of the positive fraction of pERK1/2 (upper panel) and pCD3ζ (Y142) (lower panel) in the indicated 
TCR-transduced CD8 T cell variants, pretreated (SSG, +) or not (SSG, −) with SSG, at baseline (TCR stim., −) or after 5 min of stimulation (TCR stim., +) with 
NY-ESO-1-specific unlabeled multimer (n = 2 independent experiments). Statistical analyses were performed with matched, two-way ANOVA tests followed by 
Tukey’s multiple comparisons. Significance of the adjusted p value at α = 0.05 is given by the following symbols: ns p > 0.05 and *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001, ****p ≤ 0.0001. (c) SSG-mediated fold change in the fraction of ERK1/2 (upper panel) and CD3ζ (Y142) (lower panel) phosphorylation levels for the 
indicated TCR-transduced CD8 T cell variants after 5 min stimulation. Data are depicted as box (min to max) with the middle line representing the mean. (a–c) Each 
TCR variant is depicted by distinct color codes.
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shP-1 Phosphatase activity negatively 
regulates Proximal and Distal Tcr 
signaling in a Tcr affinity-Dependent 
Manner
In order to specifically dissect the respective contributions of 
SHP-1 and SHP-2 phosphatase activity to the TCR signaling 
pathway, we next targeted SHP-1 and SHP-2 independently 
with sequence-specific CRISPR/Cas9 lentiviral constructs. We 
obtained a knock-out phenotype in a fraction of SUP-T1 cells, 
thus resulting in populations with partial deficiency of SHP-1 
(45–60%) and SHP-2 (60–80%) expression (Figures  7A and 
8A). Since SHP-1 knock-out induced a high proportion of cell 
death, in agreement with a recent report (34), this limited our 
analyses to a relatively short-time window (~7–10  days) after 
selection of the CRISPR/Cas9-targeted cells. We first evaluated 
the impact of SHP-1 knock-out on ERK1/2 phosphorylation by 
directly visualizing individual SUP-T1 cells using an imaging 
flow cytometer that enables the qualitative selection of living 
cells combined to the quantitative analysis of signaling intensity 
(38). Upon antigen-specific stimulation, we found that ERK1/2 
phosphorylation fluorescence was clearly augmented for WT, 
TMβ, and wtc51m-transduced SUP-T cells, but not for V49I cells, 
when compared to mock-targeted controls (Figure 7B).
Quantifications by phospho-flow confirmed and extended 
these results (Figure  7C). Indeed, partial SHP-1 knock-out 
resulted in the upregulation of both pCD3ζ and pERK1/2 signal-
ing molecules in all variants, with the exception of the low affinity 
V49I T cells. This led to a significant increase of the amplitude 
of CD3ζ phosphorylation (i.e., fold change between baseline 
and activated state) along the TCR affinity gradient with high-
est fold increase found in optimal and very high affinity T cells 
(Figure 7D). In the latter cells, this effect was in part due to lower 
intensity of pCD3ζ at baseline (Figure 7C). The impact of partial 
SHP-1 knock-out on the amplitude of pERK1/2 was also influ-
enced by TCR affinity, as both TMβ and wtc51m T cell variants 
displayed again the strongest fold change (Figure 7D).
shP-2 Phosphatase activity sustains 
erK1/2 Phosphorylation but Does not 
impact Proximal Tcr/cD3ζ signal initiation
Similar analyses were performed in SUP-T1 cell variants following 
CRISPR/Cas9-mediated targeting of SHP-2 phosphatase. Partial 
A B
C D
FigUre 7 | Effect of partial SHP-1 knock-out by CRISPR/Cas9 on proximal pCD3ζ and distal pERK1/2 signal intensity. (a) Representative histograms of the 
expression levels [geometric mean fluorescence intensity (gMFI)] of total SHP-1 in T cell receptor (TCR)-transduced SUP-T1 variants following CRISPR/Cas9-
mediated GFP (mock) or SHP-1 [single guide RNA (sgRNA) no 3–4 and no 5–6] targeting. Unstained (unst.) controls are shown alongside. (B) Representative 
quantitative (histograms in gMFI) and qualitative (cells) data acquired with the ImageStream flow cytometer depicting the expression levels of pERK1/2 in 
TCR-transduced SUP-T1 variants following CRISPR/Cas9-mediated GFP mock or SHP-1 targeting. Values within the histograms indicate the average expression 
levels (in gMFI) of pERK1/2 following CRISPR/Cas 9-mediated GFP mock (dark) and SHP-1 (dark) targeting after stimulation with NY-ESO-1-specific unlabeled 
multimers. (c) Quantification of the total phosphorylation levels (gMFI) of CD3ζ (Y142) (upper panels, n > 4 independent experiments) and ERK1/2 (lower panels, 
n > 4 independent experiments) by phospho-flow for the indicated TCR-transduced SUP-T1 variants following CRISPR/Cas9-mediated GFP (mock; −) or SHP-1 
(no 5–6; +) targeting, at baseline or after 5 min of stimulation with NY-ESO-1-specific unlabeled multimers. Data are depicted as box (25th and 75th percentile) and 
whisker (min to max) with the middle line representing the median. (D) Comparison of the relative differences (fold change phosphorylation levels between baseline 
and 5 min of stimulation) of pCD3ζ (Y142) (upper panels) and pERK1/2 (lower panels) for the indicated TCR-transduced SUP-T1 variants following CRISPR/
Cas9-mediated mock (−) and SHP-1 (+) targeting. Fold change (average) in phosphorylation intensity due to SHP-1 targeting is indicated for all conditions. 
Statistical analyses were performed with two-tailed, paired t tests. Significance of the p value at α = 0.05 is given by the following symbols: ns p > 0.05 and 
*p ≤ 0.05, and **p ≤ 0.01. (a–D) Each TCR variant is depicted by a distinct color code.
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SHP-2 knock-out did not induce cell death, but SUP-T1 cells were 
generally larger in size than their mock-transduced counterparts 
(data not shown). In sharp contrast to SHP-1, partial depletion of 
SHP-2 led to reduced ERK1/2 phosphorylation levels in most TCR 
variants upon TCR stimulation (Figures 8B,C). This resulted in a 
clear decline in pERK1/2 amplitude (i.e., fold change) in all TCR 
variants, except in V49I cells (Figure 8D). However, no signifi-
cant effect of SHP-2 deficiency could be detected on the intensity 
A B
C D
FigUre 8 | Effect of partial SHP-2 knock-out by CRISPR/Cas9 on proximal pCD3ζ and distal pERK1/2 signal intensity. (a) Representative Western blots of the 
expression level of total SHP-2 in T cell receptor (TCR)-transduced SUP-T1 variants following CRISPR/Cas9-mediated GFP (mock) or SHP-2 (sgRNA no 9–10) 
targeting. Alpha-tubulin expression control is shown alongside. (B) Representative quantitative (histograms in gMFI) and qualitative (cells) data acquired with the 
ImageStream flow cytometer depicting the expression levels of pERK1/2 in TCR-transduced SUP-T1 variants following CRISPR/Cas9-mediated GFP mock or 
SHP-2 targeting. Values within the histograms indicate the average expression levels (in gMFI) of pERK1/2 following CRISPR/Cas 9-mediated GFP mock (dark) and 
SHP-2 (dark) targeting after stimulation with NY-ESO-1-specific unlabeled multimers. (c) Quantification of the total phosphorylation levels (gMFI) of CD3ζ (Y142) 
(upper panels, n > 4 independent experiments) and ERK1/2 (lower panels, n > 4 independent experiments) by phospho-flow for the indicated TCR-transduced 
SUP-T1 variants following CRISPR/Cas9-mediated GFP (mock; −) or SHP-2 (+) targeting, at baseline or after 5 min of stimulation with NY-ESO-1-specific unlabeled 
multimers. Data are depicted as box (25th and 75th percentile) and whisker (min to max) with the middle line representing the median. (D) Comparison of the relative 
differences (fold change phosphorylation levels between baseline and 5 min of stimulation) of pCD3ζ (Y142) (upper panels) and pERK1/2 (lower panels) for the 
indicated TCR-transduced SUP-T1 variants following CRISPR/Cas9-mediated mock (−) and SHP-2 (+) targeting. Fold change (average) in phosphorylation intensity 
due to SHP-2 targeting is indicated for all conditions. Statistical analyses were performed with two-tailed, paired t tests. Significance of the p value at α = 0.05 is 
given by the following symbols: ns p > 0.05 and ***p ≤ 0.001. (a–D) Each TCR variant is depicted by a distinct color code.
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and amplitude of proximal CD3ζ phosphorylation compared to 
the respective mock controls (Figures 8C,D).
Altogether, CRISPR/Cas9 knock-out experiments revealed 
that SHP-1 activity mainly controls the amplitude of signal-
ing by restricting pCD3ζ and pERK1/2 activation in a TCR 
affinity-dependent manner after TCR-specific activation. On the 
other hand, our results indicate a more global positive role of 
SHP-2 phosphatase on the TCR signaling pathway by sustaining 
downstream ERK1/2 MAPK activity, without directly impacting 
on TCR/CD3ζ phosphorylation. These data are in agreement with 
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the differential impact observed on proximal versus distal TCR 
signaling molecules upon pharmacological SHP-1/2 phosphatase 
inhibition (Figure  6; Figure S5 in Supplementary Material). 
Thus, SHP-1 and SHP-2 phosphatase activities present distinct 
roles on the proximal (CD3ζ) and distal (ERK1/2) nodes of the 
TCR signaling pathway, and this was partially dependent on the 
TCR-ligand affinity.
DiscUssiOn
T cell receptor-mediated signaling can be tuned by various regu-
latory loops to transmit the surface-based inputs of TCR-pMHC 
interactions into integrated T  cell responses. During T  cell 
development, both TCR-ligand affinity and antigen dose have 
been shown to induce minute differences in the physicochemi-
cal properties of the binding strength leading in turn into large 
changes in T cell responsiveness and fate (39). The importance 
of TCR-pMHC binding strengths on the magnitude of T  cell 
responses was also demonstrated in numerous studies based on 
artificial models (e.g., using affinity-improved TCR variants or 
altered peptide ligands), highlighting that maximal T cell activa-
tion and effectiveness occur at intermediate/optimal TCR-pMHC 
binding affinities or half-lives (3, 4, 6, 8, 25, 33, 40–44). Thus, it 
was proposed that engineered TCRs against self/tumor antigens 
might not need to be enhanced beyond the physiological TCR 
affinity range (KD < 1 µM) to achieve best T cell function (45, 
46). Yet, there still is a need to improve our understanding of 
the underlying TCR signaling characteristics (i.e., amplitude, 
amplification-gain, duration) involved in generating an affinity-
optimized CD8 T cell response and to study how these parameters 
are modulated in very high affinity T cells.
Here, using the well-established panel of HLA-A*0201/
NY-ESO-1157–165-specific TCRs of incremental affinities (3, 11), 
we found that SUP-T1 and primary CD8 T  cells expressing 
TCR affinity variants in the upper natural range (KD ≈  1 μM) 
displayed the highest and most sustained CD3ζ and ERK activa-
tion levels, which was associated with maximum CD3ζ to ERK 
amplification-gain, irrespectively of the antigen dose (Figures 1, 
2 and 4; Figure S2E in Supplementary Material). Conversely, 
both lower (KD ≥  21.4  µM) and higher affinity (KD <  0.1  µM) 
TCR-transduced T cells were unable to generate strong pERK1/2 
activation and amplitude, leading to reduced functional and pro-
liferative capacities, even at high antigen dose. Temporal analysis 
further confirmed that the low affinity V49I SUP-T1 cells were at 
all time-points ineffective at generating and maintaining pCD3ζ 
signaling, which is likely due to the weak intrinsic binding capac-
ity of this TCR to the cognate pMHC (3, 11). In contrast, very 
high affinity T  cells had rapid and intense, but only transitory 
proximal signaling capacity (i.e., fully activated ITAM/pCD3ζ 
23 kDa), in line with a report showing accelerated responses in 
affinity-matured T cells specific for the HLA-A0201/Tax peptide 
(44). Our data indicate that robust and sustained proximal TCR 
signaling represents a key feature for efficient MAPK/ERK ampli-
fication and subsequent maximized T cell responsiveness. This is 
primarily determined at the intermediate/optimized TCR affinity 
range. Such observations are reminiscent of the modulations 
observed in TCR affinity-mediated ERK signaling during thymic 
positive and negative selection. Positively selected thymocytes 
that interact with low and intermediate affinity self-pMHCs dis-
play relatively mild but sustained ERK1/2 activation (47), while 
thymocytes that interact too strongly with self-pMHCs have 
intense but only transient pERK1/2, inducing negative selection 
and apoptosis (48).
Attenuation of key TCR-mediated signaling molecules in 
relation to increased TCR-ligand affinity has been previously 
documented in in  vivo mouse studies (6, 8). Sharp declines in 
Akt and STAT3 phosphorylation levels were related to limited 
IFNγ production in CD4 T cells immunized with a high affinity 
moth-cytochrome ligand (8). More recently, Zhong et al. showed 
that TCR signaling (e.g., ERK activation and calcium mobiliza-
tion) and T  cell functional responses against the self/tumor 
antigen gp-100 plateaued at a defined TCR affinity threshold (6). 
Interestingly, they also reported that T cell antitumor activity and 
autoimmunity were closely coupled, whereby increasing TCR 
affinity correlated with improved tumor control, but was also 
linked with severe ocular autoimmunity. Thus, similarly to the 
events observed during thymic selection processes, TCR affinity-
associated regulatory mechanisms may impinge on various levels 
of the TCR signaling cascade, notably at the MAPK amplification 
node, and could possibly restrict effective T cell responses.
We further found that TCR/CD3 complex triggering by the 
strong agonist OKT3/CD3ε antibody was unable to restore 
full ERK1/2 activation levels in both SUP-T1 and CD8 T  cells 
engineered with very high TCR affinities (Figure 1). Yet, these 
T cells were not ERK-defective, since TCR-independent stimula-
tion by PMA/ionomycin induced ERK1/2 activation equally 
well throughout the entire panel of affinity-increased T  cells. 
Moreover, under steady-state settings, levels of TCR/CD3 com-
plex, CD8β and CD28 expression, as well as of phosphorylated 
ITAM/CD3ζ (Y142) were also substantially decreased in the very 
high affinity T cells [Figure 3 (25)], while the baseline levels of 
phosphorylated SHP-1 and SHP-2 phosphatases were highest 
[Figure 5 (25)]. These observations are in line with the reduced 
levels of coactivatory molecules HVEM and CD70, but increased 
expression of the inhibitory receptor PD1 detected previously in 
resting primary CD8 T cells with very high affinity TCRs (25). 
Finally, no changes in basal levels were found for total CD3ε, total 
LCK, pLCK(Y394/Y416), pLCK(Y505), total ZAP-70 and pZAP-
70(Y319), nor for total ERK and pERK1/2 [Figure  3; Figures 
S1 and S2 in Supplementary Material (25)]. Together, our data 
indicate that the very high affinity SUP-T1 and CD8 T cells share 
features in common with a TCR-mediated hyporesponsive state 
and that TCR affinity-dependent regulatory mechanism(s) may 
readily be present in resting conditions. Furthermore, the TCR/
CD3 complex itself seems to be under strict affinity-dependent 
regulation and may directly or indirectly dictate differential 
activation thresholds upon TCR triggering and T cell activation. 
Thus, inducing a TCR hyporesponsive state may be part of a 
physiological protection mechanism preventing harmful effects 
that could potentially occur in response to high affinity/avidity 
TCR recognition of self-antigens.
Several tolerogenic mechanisms such as anergy- or 
exhausted-related states may have an impact on T cell activation 
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and responsiveness through TCR recognition of peptide/MHC. 
Recent findings support the notion that increasing the TCR 
signaling strength favors the induction of a hyporesponsive 
state (49, 50). For instance, it was shown in an autoimmune 
mouse model that T  cells expressing a high TCR avidity 
(either through increase of TCR-pMHC affinity or antigen 
dose) became anergic, a cell fate decision that was imprinted 
by PD-1 upregulation and pERK1/2 inhibition (49). Hsu et al. 
further reported that peripheral CD4 T  cells with a ZAP-70 
gain-of-function mutation inducing enhanced basal TCR sign-
aling displayed a T cell anergy-like phenotype with increased 
expression of PD-1 (50). At present, it remains unclear what 
causes the TCR-mediated hyporesponsive state observed in 
engineered CD8 T cells of very high but not intermediate TCR 
affinity, readily detectable under resting culture conditions. 
Through structure-based rational predictions, the TCR affinity-
optimization process used here were achieved by the combi-
nation of point mutations within the CDR2α and/or CDR2β 
and/or CDR3β loops (3, 12). Specifically, TMβ and QMα TCR 
variants contain 2 and 3 mutations within the CDR2α/β loops, 
respectively. Moreover, we also included the very high affinity 
TCR variant wtc51m, previously identified by phage-display 
screening, and containing up to four mutations in the CDR2β 
loop (51). Importantly, our TCR affinity-improved panel 
remained ligand-specific and retained similar TCR-pMHC 
binding recognition patterns compared to the wild-type TCR 
(3). Therefore, one likely hypothesis is that the gain in affinity 
(KD < 1 µM) within our panel of engineered T cells is mainly 
related to amino acid mutations within the CDR2α/β loops, 
mostly interacting with the HLA-A2 backbone (3). In the very 
high affinity T cells (KD < 1 µM), this may trigger chronic TCR-
HLA-A2 binding interactions, even in the absence of cognate 
peptide antigen, resulting in a hyporesponsive cellular and 
functional state. Preliminary results support this hypothesis, 
since reduced CD28 and TCR β-chain (BV13.1) expression in 
very high affinity TCR variants was predominantly found in 
HLA-A2pos TCR-engineered CD8 T cells when compared to the 
corresponding HLA-A2neg cells (Figure 3F, Duong M.-N. et al., 
unpublished data). This was associated with the upregulation of 
immune modulators such as PD-1 in HLA-A2pos but not HLA-
A2neg engineered CD8 T cells (Duong M.-N. et al., unpublished 
data). Future analysis involving the careful evaluation of the 
molecular combined to functional regulation of this TCR 
affinity-dependent hyporesponsive state is necessary to under-
stand the precise contribution of the TCR-HLA-A2-mediated 
interactions in our TCR affinity-increased model. Our observa-
tions are further consistent with a report (52) describing the 
importance of TCR-peptide/self-MHC interactions in control-
ling basal T cell activation levels and the ensuing T cell respon-
siveness to foreign antigen. Namely, in the absence of self-MHC 
recognition on dendritic cells, T cells became impaired in TCR/
CD3ζ-mediated signaling, and consequently hyporesponsive to 
antigen, leading to reduced T cell proliferative responses (52). 
Together, we propose that adjusted TCR-peptide/self-MHC 
interactions might be essential in setting an optimal basal T cell 
activation threshold for subsequent agonist-dependent TCR 
signaling initiation and T cell function.
Our work offers clear evidence that SHP-1 and SHP-2 
phosphatase activities have an opposite biological impact on 
the ERK signaling node (Figures  6–8). While reduced SHP-1 
expression upon CRISPR/Cas9 revealed significant increased 
ERK1/2 phosphorylation, SHP-2 depletion led to a clear decline 
in ERK1/2 activation levels. Besides, the SHP-1-mediated effect 
was mostly observed in the higher affinity SUP-T1 cells, differing 
from the SHP-2-mediated one, which affected both physiological 
and supraphysiological affinity TCR variants. Similarly, SHP-1 
but not SHP-2 activity had an impact on proximal TCR/CD3ζ 
signal initiation, in a TCR affinity-dependent manner. Indeed, we 
found an increase in CD3ζ activation upon partial SHP-1 knock-
out, which is consistent with the known implication of SHP-1 
in counteracting TCR signal initiation, likely through the direct 
dephosphorylation of CD3ζ (53). In contrast, no significant effect 
of SHP-2 deficiency was found on the intensity or the amplitude 
of CD3ζ phosphorylation. In light of these results, pharmaco-
logical inhibition by SSG at a concentration known to affect both 
SHP-1 and SHP-2 phosphatases (30) yielded comparable results 
in TCR-engineered primary CD8 T and SUP-T1 cells. Our data 
suggest that the TCR affinity-associated increase in ERK1/2 
phosphorylation observed after SHP-1 inhibition (Figure 7) may 
compensate the general decrease of pERK1/2 detected after SHP-2 
depletion (Figure 8). Following SHP-1/SHP-2 inhibition by SSG, 
this would result in relative pERK levels being less reduced in 
very high affinity T cells compared to optimal or wild-type ones 
(Figure 6; Figure S5 in Supplementary Material), in which the 
impact of SHP-1 inhibition is less prevalent. Moreover, the small 
yet positive increase in pCD3ζ levels along the TCR affinity gradi-
ent upon SSG treatment further argues in favor of a predominant 
role of SHP-1 phosphatase at the proximal TCR signaling node. 
Collectively, our data indicate that SHP-1 activity negatively 
modulates proximal (CD3ζ) and distal (ERK1/2) TCR signaling 
in a TCR affinity-dependent manner, while SHP-2 activity plays 
a more global and positive impact in promoting downstream 
ERK1/2 MAPK activity.
SHP-1 is generally viewed as a negative regulator of the TCR-
mediated signaling cascade, whereas SHP-2 appears to play a 
more complex role, likely resulting from its several potential 
targets as well as their spatial level (i.e., proximal versus distal) 
within the TCR and coactivatory signaling pathways. For 
instance, the transient association between PD-1 receptor and 
SHP-2 into so-called inhibitory microclusters mediates the 
dephosphorylation of proximal TCR signaling molecules, in 
a TCR stimulation strength-dependent manner (23). A recent 
study further revealed that the costimulatory molecule CD28 
is a preferred target over the TCR for dephosphorylation by 
PD-1-recruited SHP-2 phosphatase (24). This is in line with the 
absence of SHP-2-associated impact on CD3ζ phosphorylation 
in the present study, mainly because we specifically triggered the 
TCR signaling cascade using multimers. Our results are also in 
agreement with the reported positive role of SHP-2 in promoting 
ERK1/2 activation (21, 54, 55), although this was not directly 
related to the TCR affinity-dependent increase in pSHP-2 
(Y542 and Y580) levels observed after TCR-specific triggering 
(Figure 5). Indeed, highest levels of pSHP-2 were seen in the very 
high affinity T cells and occurred early after stimulation (30 sec, 
17
Presotto et al. TCR Affinity-Mediated Signaling Regulation
Frontiers in Immunology | www.frontiersin.org November 2017 | Volume 8 | Article 1564
Figure  5), but this phosphorylation pattern was not mirrored 
by pERK1/2 upregulation, taking place later and mainly in the 
optimal affinity TCR variants (≥2 min; Figure 1; Figure S1 in 
Supplementary Material). Several explanations could account for 
this observation. First, these data are in accordance to the rapid 
but transient proximal signals (pCD3ζ and pLCK/Src) found in 
T cells with very high affinity TCRs, yet resulting in poor MAPK 
activation and low proliferative capacity (Figure 2; Figure S2 in 
Supplementary Material). This was also associated with lowest 
pCD3ζ to pERK amplification gain in comparison to optimal 
TCR variants (Figure 4). Together, our findings further support 
the notion that TCR affinity-dependent regulatory mechanisms 
may upon TCR triggering, rapidly counteract downstream 
propagation and amplification signals, thus calibrating optimal 
signaling and subsequent function within the physiological TCR 
affinity range. An alternative explanation may come from the 
dual (i.e., positive versus negative) role of SHP-2 played at dis-
tinct nodes of the TCR signaling pathway (22), which may hide 
a potential TCR affinity-dependent impact, resulting in a more 
global SHP-2 activity-mediated effect on pERK1/2 (Figure  8). 
In contrast, SHP-1 phosphatase was found to exert a clear 
negative effect on the proximal CD3ζ signal activation in a TCR 
affinity-dependent manner, which may further translate to the 
distal MAPK node (Figure 7). Finally, it was recently shown that 
SHP-1’s phosphorylation status does not necessarily correspond 
to its phosphatase activity (56). Given the structural homology 
existing between SHP-1 and SHP-2 phosphatase (18), this may 
also occur for SHP-2, but remains to be determined.
Two models have been proposed to describe the molecular 
mechanisms involving SHP-1 phosphatase in regulating T cell 
output signals in relation to TCR-ligand affinity. In the first one, 
SHP-1 acts as a negative feedback loop in response to antagonist 
or weak TCR stimulation through its direct interaction with 
LCK, leading to subsequent inhibition of TCR signaling (35). 
In turn, stronger TCR activation induces an ERK-dependent 
phosphorylation of LCK at Ser59, blocking SHP-1 binding to 
LCK and enabling positive TCR signal amplification and main-
tenance. Interestingly, this model nicely fits with the pattern of 
pERK1/2 detected in our panel of CD8 T cells, whereby optimal 
affinity cells exhibited highest MAPK activity in contrast to 
low affinity T  cells. Moreover, the LCK-ERK-SHP-1-mediated 
mechanism may also be involved in the supraphysiological 
affinity T  cells, as preliminary data suggest that LCK-Ser59 
phosphorylation pattern mirrors the pERK1/2 bell-shape one 
along the TCR affinity gradient (unpublished data). In fact, 
maximal LCK-Ser59 phosphorylation levels were found in the 
optimal affinity T cells, compared to low and very high affinity 
cells. However, in-depth temporal evaluation of ERK-mediated 
LCK/Ser59 phosphorylation within our affinity-increased CD8 
T cell panel, as well as its functional relevance should deserve 
further investigations, since knock-in-targeted replacement of 
LCK-Ser59 by alanine did not affect TCR signaling and ligand 
discrimination in an in  vivo model (34). The second model 
proposes that SHP-1 as well as SHP-2 constitutively interact with 
THEMIS, a key TCR signal regulator for ligand discrimination, 
which upon TCR triggering recruits both phosphatases to the 
LAT/GRB2 signalosome complex (34, 57). THEMIS was initially 
proposed to act as a negative regulator of TCR signaling via 
SHP-1 by regulating neighboring TCR signaling targets (57). 
However, recent studies have refined this view by showing that 
THEMIS may in fact have a positive effect on TCR signaling 
during thymocyte development, notably by suppressing SHP-1 
tyrosine-phosphatase activity (56, 58). Together, these observa-
tions demonstrate a critical role of the THEMIS-SHP complex 
during thymocyte development as a fine-tuner of TCR signaling 
threshold, but whether similar regulatory mechanisms also 
apply within our model of affinity-improved T cells remains to 
be determined.
Our findings have implications in the design of affinity-
improved TCRs for immunotherapy, since it is becoming 
clear that regulatory signaling mechanisms are associated 
with increasing TCR-ligand affinity in TCR-redirected CD8 
T  cells. Moreover, identifying the key regulatory molecules 
triggering TCR hyporesponsiveness in very high affinity CD8 
T cells is also relevant in our understanding of T cell-mediated 
immune tolerance processes, as they might potentially offer 
new molecular targets that could be modulated during CD8 
T cell responses.
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SUPPLEMENTAL MATERIALS  
AND METHODS
cD107a Degranulation and intracellular cytokine 
staining assays
Native NY-ESO-1157-165 peptides were incubated for 1  hour at 
room temperature with the disulfide-reducing agent TCEP 
(2  mM, Pierce Biotechnology). HLA-A*0201-positive TAP-
deficient T2 cells were pulsed 1 hour at 37°C with varying doses 
of NY-ESO-1157-165, peptide, washed and incubated with TCR-
transduced primary CD8 T cells at an E:T ratio of 1:2 for 4 hours 
in the presence of anti-CD107a/LAMP1 (FITC, clone H4A3) 
(BD Pharmingen) and Brefeldin A (10 µg/ml, Sigma). Cells were 
stained with anti-CD8α Pacific-Blue (clone B9.11) (Beckman 
Coulter) at 4°C for 30 min, subsequently fixed in 1% formaldehyde, 
2% glucose and 5 mM NaN3 for 20 min at RT and permeabilized 
with 0.1% Saponin (Sigma Aldrich). Samples were then stained 
with anti-IL-2 (PerCP-Cy5.5, clone MQ1-17H12), anti-IL-13 
(APC, clone JES10-5A2), anti-IFNγ (PE-Cy7, clone 4 S.B3) and 
anti-TNFα (Alexa Fluor700, clone Mab11) (BD Pharmingen) and 
anti-IL-4 (PE, clone MP4-25D2) (Biologend) for 30 min at 4°C. 
The samples were acquired with a Gallios (Beckman Coulter, CA, 
USA) flow cytometer. The data analysis was done on FlowJo (Tree 
star) and Prism (Graphpad, USA) platforms.
FigUre s1 | Analysis of the expression levels of pERK1/2 signal by the RPPA 
technology. (a) Relative intensity of ERK1/2 phosphorylation levels at baseline 
and at the indicated time-points after stimulation of the TCR-transduced SUP-T1 
variants with NY-ESO-1-specific unlabeled multimers (n = 8 independent 
experiments). (B) Relative intensity of total ERK1/2 expression levels at baseline 
and at the indicated time-points after stimulation of the TCR-transduced SUP-T1 
variants with NY-ESO-1-specific unlabeled multimers (n = 8 independent 
experiments). Statistical analyses were performed with matched, one-way 
ANOVA tests followed by Dunnett’s multiple comparisons. Significance of the 
adjusted p value at α = 0.05 as following: **p ≤ 0.01, ***p ≤ 0.001, 
****p ≤ 0.0001. Data are depicted as box (25th and 75th percentile) and whisker 
(min to max) with the middle line representing the median. (a–c) Each TCR 
variant is depicted by a distinct color code.
FigUre s2 | Expression level of pLCK/Src(Y394/Y416), pLCK(Y505) and total 
LCK by the RPPA technology. (a–c) Relative intensity of activatory LCK/
Src(Y394/Y416) phosphorylation (n = 4 independent experiments) (a), inhibitory 
LCK(Y505) phosphorylation (n = 5 independent experiments) (B) and total LCK/
Src expression (n = 5 independent experiments) (c) levels by RPPA at baseline 
and at the indicated time-points after stimulation of the TCR-transduced SUP-T1 
variants with NY-ESO-1-specific unlabeled multimers. Statistical analyses were 
performed with matched, one-way ANOVA tests followed by Dunnett’s multiple 
comparisons. Data are depicted as box (25th and 75th percentile) and whisker 
(min to max) with the middle line representing the median. (D) Quantification of 
the phosphorylation levels (in gMFI) of unstimulated, baseline CD3ζ (Y142) and 
ERK1/2(T202/Y204) for the indicated TCR-transduced primary CD8 T cell 
variants. Data are representative of 6–12 independent experiments. (e) 
Quantification of the signal amplification gain (relative fold increase) from pCD3ζ 
(Y142) to pERK1/2 following 30 min after stimulation of the indicated TCR-
transduced SUP-T1 variants with NY-ESO-1-specific unlabeled multimers. (a–e) 
Each TCR variant is depicted by the same distinct color code.
FigUre s3 | Antigen dose titration experiments of degranulation and cytokine 
production in TCR-transduced primary CD8 T lymphocytes. (a) Representative 
histograms of an intracellular staining experiment showing the intensity of 
degranulation (CD107a/LAMP1) and the expression levels of IFNγ, TNFα, IL-2, 
IL-4 and IL-13 in primary CD8 T cells transduced with an independent panel of 
affinity-optimized TCRs (T2A linked alpha and beta TCR panel) after 4 hours of 
incubation with TAP-deficient T2 cells pulsed with graded amounts of native 
NY-ESO-1157-165 peptide. (n = 4 independent experiments) (B) Quantification of 
the CD107a/LAMP1 degranulation intensity and the expression levels of the 
indicated cytokines. Data obtained from the different antigen doses (0.01, 0.1, 1, 
and 10 µM) are depicted as individual curves.
FigUre s4 | Expression level of pSHP-1(Y536) and total SHP-1 by the RPPA 
technology. (a,B) Relative intensity of SHP-1(Y536) phosphorylation (n = 5 
independent experiments) (a) and total SHP-1 expression (n = 3 independent 
experiments) (B) levels at baseline and at the indicated time-points after 
stimulation of the TCR-transduced SUP-T1 variants with NY-ESO-1-specific 
unlabeled multimers. Statistical analyses were performed with matched, one-way 
ANOVA tests followed by Dunnett’s multiple comparisons. *p ≤ 0.05, **p ≤ 0.01, 
***p ≤ 0.001.
FigUre s5 | Effect of sodium stibogluconate (SSG) on proximal pCD3ζ and 
distal pERK1/2 signal intensity in TCR-transduced SUP-T1 cells. (a) 
Representative histograms of the phosphorylation levels (gMFI) of ERK1/2 (left) 
and CD3ζ (Y142) (right) by phospho-flow at baseline (gray) and 5 min 
poststimulation with NY-ESO-1-specific unlabeled multimers (color) of 
TCR-transduced SUP-T1 cells pretreated (SSG) or not (mock) with sodium 
stibogluconate. (B) Quantification of the positive fraction of pERK1/2 (upper 
panel) and pCD3ζ (Y142) (lower panel) in the indicated TCR-transduced SUP-T1 
cells, pretreated (SSG, +) or not (SSG, −) with sodium stibogluconate, at 
baseline (TCR stim., −) or after 5 min of stimulation (TCR stim., +) with 
NY-ESO-1-specific unlabeled multimers (n = 4 independent experiments). 
Statistical analyses were performed with matched, two-way ANOVA tests 
followed by Tuckey’s multiple comparisons. Significance of the adjusted p value 
at α = 0.05 is given by the following symbols: ns p > 0.05 and *p ≤ 0.05, 
**p ≤ 0.01, ***p ≤ 0.001, ****p ≤ 0.0001. (c) SSG-mediated fold change in the 
fraction of ERK1/2 (upper panel) and CD3ζ (Y142) (lower panel) phosphorylation 
levels for the indicated TCR-transduced SUP-T1 cells after 5 min of stimulation. 
Data are depicted as box (min to max) with the middle line representing the 
mean. (A–C) Each TCR variant is depicted by a distinct color code.
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